Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD.

about

Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD.

Item

http://www.wikidata.org/entity/Q42729433

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Subretinal recombinant tissue ...... i-VEGF injections for wet AMD.

@en

Subretinal recombinant tissue ...... i-VEGF injections for wet AMD.

@nl

type

Item

label

Subretinal recombinant tissue ...... i-VEGF injections for wet AMD.

@en

Subretinal recombinant tissue ...... i-VEGF injections for wet AMD.

@nl

prefLabel

Subretinal recombinant tissue ...... i-VEGF injections for wet AMD.

@en

Subretinal recombinant tissue ...... i-VEGF injections for wet AMD.

@nl

P1476

Subretinal recombinant tissue ...... i-VEGF injections for wet AMD.

@en

P2093

Eirini Skiadaresi

http://www.w3.org/2001/XMLSchema#string

Giuseppe Ravalico

http://www.w3.org/2001/XMLSchema#string

Paolo Cecchini

http://www.w3.org/2001/XMLSchema#string

P2860

Ranibizumab for neovascular age-related macular degeneration

Management of submacular hemorrhage with intravitreal sulfur hexafluoride: a pilot study.

Surgical extraction of subfoveal choroidal new vessels and submacular haemorrhage in age-related macular degeneration: results of a prospective study.

Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration.

Pneumatic displacement of a dense submacular hemorrhage with or without tissue plasminogen activator.

Large submacular hemorrhage following PDT with verteporfin in patients with occult CNVM secondary to age-related macular degeneration.

Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.

[Chances and risks of anti-VEGF therapy].

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.

P304

459-463

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.2147/OPTH.S15864

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Tognetto

P577

2011-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21573092

http://www.w3.org/2001/XMLSchema#string

P932

3090299

http://www.w3.org/2001/XMLSchema#string